Page 97 - 2019年10月第30卷第19期

safety of immunosuppressant therapy after heart transplan- outcomes in Korean kidney transplant recipients[J]. Eur J
tation[J]. Pharmacogenomics，2015，16（9）：971-979. Clin Pharmacol，2012，68（5）：657-669.
[ 4 ] SHILBAYEH S. The impact of genetic polymorphisms on [14] SODA M，FUJITANI M，MICHIUCHI R，et al. Associa-
time required to attain the target tacrolimus levels and sub- tion between tacrolimus pharmacokinetics and cyto-
sequent pharmacodynamic outcomes in pediatric kidney chrome P450 3A5 and multidrug resistance protein 1 exon
transplant patients[J]. Saudi J Kidney Dis Transpl，2014， 21 polymorphisms[J]. Transplant Proc，2017，49（6）：
25（2）：266-277. 1492-1498.
[ 5 ] MEANEY CJ，ARABI Z，VENUTO RC，et al. Validity [15] NAITO T，MINO Y，AOKI Y，et al. ABCB1 genetic vari-
and reliability of a novel immunosuppressive adverse ef- ant and its associated tacrolimus pharmacokinetics affect
fects scoring system in renal transplant recipients[J]. BMC renal function in patients with rheumatoid arthritis[J]. Clin
Nephrol，2014.DOI：10.1186/1471-2369-15-88. Chim Acta，2015，445（5）：79-84.
[ 6 ] KRAVLJACA M，PEROVIC V，PRAVICA V，et al. The [16] ZHANG X，WANG Z，FAN J，et al. Impact of interleu-
importance of MDR1 gene polymorphisms for tacrolimus kin-10 gene polymorphisms on tacrolimus dosing require-
dosage[J]. Eur J Pharm Sci，2016.DOI：10.1016/j.ejps. ments in Chinese liver transplant patients during the early
2015.12.020. posttransplantation period[J]. Eur J Clin Pharmacol，
[ 7 ] CUSINATO DA，LACCHINI R，ROMAO EA，et al. Rela- 2011，67（8）：803-813.
tionship of CYP3A5 genotype and ABCB1 diplotype to ta- [17] CHAKKERA HA，CHANG YH，BODNER JK，et al. Ge-
crolimus disposition in Brazilian kidney transplant patients netic differences in Native Americans and tacrolimus dos-
[J]. Br J Clin Pharmacol，2014，78（2）：364-372. ing after kidney transplantation[J]. Transplant Proc，2013，
[ 8 ] KNOPS N，LEVTCHENKO E，VAN DEN HEUVEL B， 45（1）：137-141.
et al. From gut to kidney：transporting and metabolizing [18] HODGES LM，MARKOVA SM，CHINN LW，et al. Very
calcineurin-inhibitors in solid organ transplantation[J]. Int important pharmacogene summary：ABCB1（MDR1，P-
J Pharm，2013，452（1/2）：14-35. glycoprotein）[J]. Pharma-cogenet Genom，2011，21（3）：
[ 9 ] KATO T，SATO Y，KUROSAKI I，et al. FK506 may re- 152-161.
duce early liver injury following living related liver trans- [19] MARZOLINI C，PAUS E，BUCLIN T，et al. Polymorphi-
plantation[J]. Hepatogastroenterology，2006，53（70）： sms in human MDR1（P-glycoprotein）：recent advances
580-583. and clinical relevance[J]. Clin Pharmacol Ther，2004，75
[10] YANG TH，CHEN YK，XUE F，et al. Influence of CYP3A5 （1）：13-33.
genotypes on tacrolimus dose requirement：age and its [20] HAAS DW，BARTLETT JA，ANDERSEN JW，et al. Ph-
pharmacological interaction with ABCB1 genetics in the armacogenetics of nevirapine-associated hepatotoxicity：
Chinese paediatric liver transplantation[J]. Int J Clin an adult AIDS clinical trials group collaboration[J]. Clin
Pract，2015，69（183）：53-62. Infect Dis，2006，43（6）：783-786.
[11] MENDES J，MARTINHO A，SIMOES O，et al. Genetic [21] RITCHIE MD，HAAS DW，MOTSINGER AA，et al.Drug
polymorphisms in CYP3A5 and MDR1 genes and their transporter and metabolizing enzyme gene variants and
correlations with plasma levels of tacrolimus and cyclo- nonnucleoside reverse-transcriptase inhibitor hepatotoxici-
sporine in renal transplant recipients[J]. Transplant Proc， ty[J]. Clin Infect Dis，2006，43（6）：779-782.
2009，41（3）：840-842. [22] CICCACCI C，BORGIANI P，CEFFA S，et al. Nevirap-
[12] THISHYA K，VATTAM KK，NAUSHAD SM，et al. Artifi- ine-induced hepatotoxicity and pharmacogenetics：a retro-
cial neural network model for predicting the bioavailabili- spective study in a population from Mozambique[J]. Phar-
ty of tacrolimus in patients with renal transplantation[J]. macogenomics，2010，11（1）：23-31.
PLoS One，2018，13（4）：e0191921. （收稿日期：2019-03-12 修回日期：2019-06-06）
[13] KIM IW，MOON YJ，JI E，et al. Clinical and genetic fac- （编辑：邹丽娟）
tors affecting tacrolimus trough levels and drug-related

·2684 · China Pharmacy 2019 Vol. 30 No. 19 中国药房 2019年第30卷第19期